AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.